Open access peer-reviewed chapter

Gene-based Interventions for Cancer Immunotherapy

Written By

Otto L.D. Cerqueira, Gissele Rolemberg Oliveira Silva, Igor de Luna Vieira, Marlous Vinícius Gomes Lana, Nadine Gimenez, Otavio Augusto Rodrigues, Paulo Roberto Del Valle, Samir Andrade Mendonça and Bryan E. Strauss

Submitted: January 17th, 2018 Reviewed: July 18th, 2018 Published: November 5th, 2018

DOI: 10.5772/intechopen.80386

Chapter metrics overview

1,100 Chapter Downloads

View Full Metrics


Immunotherapy of cancer has deservedly gained much attention in the past few years and is likely to continue to advance and become a fundamental cancer treatment. While vaccines, chimeric antigen receptor (CAR) T cells and checkpoint blockade have received the lion’s share of the attention, an important direct role for gene transfer as an immunotherapy is emerging. For example, oncolytic viruses induce immunogenic cell death, thus liberating both antigens and the signals that are necessary for the activation of antigen-presenting cells, ensuring stimulation of an adaptive response. In another example, transfer of prodrug converting enzymes, such as the herpes simplex virus-thymidine kinase (HSV-tk) gene or the cytosine deaminase gene, has been shown to promote an immune response, thus functioning as immunotherapies. Alternatively, our own work involves the use of nonreplicating viral vectors for the simultaneous delivery of gene combinations that promote both cell death and an immune response. In fact, our gene transfer approach has been applied as a vaccine, immunotherapy or in situ gene therapy, resulting in immunogenic cell death and the induction of a protective immune response. Here, we highlight the development of these approaches both in terms of technical advances and clinical experience.


  • vaccine
  • CAR-T cell
  • oncolytic virotherapy
  • suicide gene
  • viral vectors

1. Introduction

The idea that the immune system acts as one of the barriers to the emergence and progression of tumors was conceived more than a 100 years ago [1]. Frank Macfarlane Burnet proposed the concept of “antitumor surveillance,” which postulated that the immune system acted as a sentinel that controls and eliminates malignant cells [2]. This hypothesis was much debated and the lack of experimental evidence due to the technological limitations of the time generated a heated debate [3]. However, extensive data presented in the literature have since strengthened and expanded this concept [4, 5, 6, 7, 8].

The elaboration of appropriate immune responses must include the detection of the “self” and “nonself” antigens. For this, the immune system must not react to self-antigens and, at the same time, must detect threats to the organism, whether internal or exogenous. Tumors are particularly complex since these unwanted cells arise from the body’s own tissues. Thus, upon detection of tumor cells, the immune system must strike a fine balance between activation of effector responses and tolerance. The immune system exploits the tenuous differences between normal cells in homeostasis and intrinsically related tumor cells.

Considering the high rate of mutation in tumors, the newly formed protein variants generate neoepitopes that may serve as targets for the detection and elimination of these aberrant and decontextualized cells by the immune system. These neoantigens can be, for example, the result of mutations caused by dysfunctional chromosomal recombination, such as the Philadelphia chromosome, generating a BCR-ABL gene fusion that did not previously exist in the body. This is a classic example of tumor-specific antigen (TSA), as seen in Table 1. Among the solid tumors, melanoma has the highest mutation rate (0.5 to >100 mutations per megabase), which reinforces the hypothesis that it is a highly immunogenic tumor [9]. Another characteristic of tumor cells is that they can express, or overexpress, genes outside the homeostatic context of their microenvironment, such tumor-associated antigens (TAAs) include oncofetal genes (linked to embryogenesis) or tissue markers, such as in melanoma (MAGE) or in breast cancer (HER2) [10]. These neoantigens and deregulated/overexpressed proteins are important targets for immunotherapeutic approaches.

Human tumor Antigenic protein
Melanoma, esophageal and liver carcinoma MAGE
Melanoma Tyrosinase
Breast and ovarian carcinomas HER2/Neu
Prostate carcinoma Prostate-specific antigen (PSA)
Head-and-neck carcinoma Caspase 8
Chronic myelogenous leukemia (CML) BCR-ABL
Colon carcinoma Carcinoembryonic antigen (CEA)

Table 1.

Examples of TAA and TSA recognized by T cells.

Although antitumor immune responses do occur, tumors often develop elaborate strategies of evasion. This fundamental hallmark of cancer encompasses a wide variety of mechanisms and appears to exploit multiple levels and different cell types in the immune system, acting like a network. These mechanisms include (i) immunoediting, where the selection of variants of nonimmunogenic tumor cells (a phenomenon also known as immunoselection) is due to low expression of immunogenic molecules (like TAA) and/or major histocompatibility complex-I (MHC-I) molecules, and (ii) immuno-subversion, where immune suppressor signals are generated, thus disarming antitumor defenses [5, 7, 11].

These antitumor immune responses rely on innate and adaptive mechanisms. NK (natural killer) cells, part of the innate immune response, recognize MHC-I molecules (through the NKG2D receptor) and eliminate cells that have null or low expression. In addition, danger-associated molecular patterns (DAMPs) and stress-signaling proteins (MICA, MICB, ULBP4) signal an NK attack on cells that have suffered damage and that should be eliminated. Conditions such as irreparable levels of mutations and viral infections naturally trigger this signaling. However, the neoplastic cells can downregulate the expression of these stress markers and MHC-I or may secrete soluble MICA, thus avoiding NK cell attack [12].

Adaptive immunity also undergoes profound changes during tumor progression. Suppressive immune responses include the formation and recruitment of regulatory T lymphocytes (Treg), which, under normal conditions, inhibit the immune system’s response to self-antigens [11]. In the tumor context, this mechanism is subverted to suppress antitumor immune responses, generating tolerance to tumor antigens [13, 14, 15]. These infiltrating Tregs contribute to the establishment of a tumor microenvironment abundant in immunosuppressive factors (IL-10, TGF-β, Arg1 and IDO) that influence many different cellular types, including the inhibition of effector T lymphocytes (Teff), generation of myeloid-derived suppressor cells (MDSC) and impairment of the proper function of dendritic cells (DCs) for presenting antigens [7].

The immunosuppressive tumor microenvironment also influences the immune checkpoint status, promoting the expression of inhibitory checkpoint molecules (CTLA-4, PD-1, IDO, LAG3, TIM3 and KIR) to the detriment of stimulatory checkpoint molecules (OX40, CD27, CD28, CD40, CD122 and ICOS) [16]. On the other hand, understanding this phenomenon brings interesting perspectives for immunotherapies as discussed below.


2. Immune interventions promoting active responses against tumor cells

Therapeutic strategies that target immune activation have shown significantly increased survival and quality of life for cancer patients [17]. Cancer immunotherapy comprises a variety of treatment approaches and combinations, incorporating the specificity of the adaptive immune response (T cells and antibodies) as well as the diverse and potent cytotoxic weaponry of both adaptive and innate immunity [18]. In this section, we provide an overview of key immunotherapeutic approaches.

Some of these strategies involve the application of soluble antibody molecules that specifically recognize and bind TAAs, resulting in blocked receptor signaling and/or passive immunotherapy. In particular, targeting tumor cells by engaging surface antigens differentially expressed in cancers has been widely used. For example, rituximab targets CD20 in non-Hodgkin B cell lymphoma. At least nine monoclonal antibodies (mAbs) targeting six TAAs (HER2/Neu, EGFR, VEGF, CD20, CD52 and CD33) are approved for the treatment of solid and hematological malignancies [19].

Approved by the Food and Drug Administration (FDA) in 2011, ipilimumab is a mAb against cytotoxic T lymphocyte–associated protein 4 (CTLA-4), a negative checkpoint of T cell function. Thus, checkpoint blockade with ipilimumab releases the brakes of the immune system, promoting T cells to combat cancer cells, and has already benefited thousands of patients with advanced melanoma, a disease that typically kills in less than a year [20]. Additional targets of immune checkpoint therapy include programmed cell death protein 1 (PD1) and its ligand PD-L1, which are even more effective and have fewer side effects as compared to anti-CTLA4 [21]. Moreover, checkpoint inhibitors may be used in combination with each other or with other therapies resulting in the induction of sustained antitumor responses in a wide variety of tumors [22, 23, 24, 25]. Checkpoint blockade has undoubtedly been one of the most impressive advancements in cancer therapeutics in recent years, prolonging and saving the lives of many cancer patients. Even so, this approach does not directly induce a de novo immune response but releases experienced T cells from inhibitory signaling.

Vaccines are strategies to activate effector immune cells upon stimulation with tumor antigens, promoting the patient’s own immune system to mount an immune response against neoplastic cells. Numerous vaccine approaches have been attempted and share the goal of providing effective target antigens while reverting, perhaps, the immunosuppressive tumor microenvironment and activating the ability of DCs to present these antigens. One example is GVAX (Cell Genesys, Inc., South San Francisco, CA), a polyvalent vaccine derived from a cultured cancer cell line expressing a plurality of shared tumor antigens. In addition, the cells have been genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-modulatory cytokine that can activate antigen-presenting cells (APCs) locally at the vaccine site. Indeed, autologous and/or allogeneic GM-CSF-secreting tumor cell vaccines have demonstrated evidence of immunologic responses in patients with various types of cancers, for example, chronic myeloid leukemia [26], melanoma [27], pancreatic adenocarcinoma [28] and prostate cancer [29].

Oncolytic virotherapy (OV) is a novel form of cancer therapy that employs native or engineered viruses that selectively replicate in and kill cancer cells. OVs act as immunotherapies, promoting antitumor responses due to the viral infection of tumor cells and their acute lysis. An example of this therapy is an intralesional injection with talimogene laherparepvec (Imlygic, T-VEC, Amgen, Thousand Oaks, CA), a genetically engineered oncolytic HSV (herpes simplex virus), with mutations in infectious cell proteins (ICPs) 34.5 and 47, and expressing US11 and GM-CSF [30].

Alternatively, the patient’s own T cells or NK cells may be used as a therapeutic agent. Such adoptive cell therapy (ACT) involves the recovery and ex vivo expansion of the patient’s cells, providing the opportunity for selection and activation of tumor-specific populations, before they are infused in the patient [31]. One of the most advanced ACTs in clinical use is called CAR (chimeric antigen receptor) T cell therapy, which involves genetic modification of the patient’s T cells to enhance their ability to recognize and attack cancer cells [32]. CAR-T cells have been engineered to express multiple CARs that recognize several tumor antigens. This technology has been successfully applied in clinical trials for hematological malignancies, with durable and complete remission in acute lymphoblastic leukemia [33], chronic lymphocytic leukemia [34] and B-cell lymphomas [35]. Another interesting application is the introduction of CARs targeting negative regulatory receptors, such as PD-1, resulting in reversal of immunosuppression in the tumor [36].

While cancer immunotherapies continue to evolve, the recurring role for gene transfer as a fundamental component of many of these approaches is quite evident. Here, we explore several immunotherapy approaches that rely on some aspects of gene transfer, highlighting both clinical and technological advances, especially as related to virotherapy, suicide genes, vaccines and CAR-T cells.


3. Cancer vaccines

Genetic instability intrinsic to cancer generates innumerable missense mutations in tumor cells and thus generates specific targets for T cell immunity [37]. Since these neoantigens are not expressed in normal somatic cells, they are inviting targets for the development of cancer vaccines and rational combinations of immunotherapies [38].

Although the term vaccine initially referred to the use of prophylactic immunizations for bacterial or viral infections, there are vaccines for therapeutic purposes, especially when we refer to cancer. This strategy has been gaining prominence lately as it offers the opportunity for a lasting effector response and with far fewer side effects than established traditional treatments, such as chemotherapy. In general terms, cancer vaccines seek to restore the ability of the immune system to recognize and eliminate neoplastic cells. In addition, the possibility of generating memory T cells favors long-lasting protective effects, including the prevention of metastasis after primary remission, which would greatly increase the survival and quality of life of these patients.

One of the earliest reports of cancer immunotherapy was conducted by William B. Coley. After observing that established tumors associated with fever or infection generally had higher rates of spontaneous regression, Streptococcus (Coley’s toxin) was injected into an inoperable bone tumor. Despite generating data with difficult interpretation, it sparked a debate and numerous other fronts of investigation [39]. Corroborating this hypothesis, Lamm et al. demonstrated that Bacillus Calmette-Guerin (BCG) could be used to activate the immune system and thus enable the treatment of bladder cancer. This therapy, approved by the FDA, is still in clinical use [40].

3.1. Improving vaccine efficacy

In both of the pioneering works described above, bacterial components having immunostimulatory properties were used. It is now clear that the formulation of vaccines should include adjuvants, important components for immunomodulatory actions or acting as delivery systems for vaccine antigens [41, 42, 43]. The adjuvants’ property of modulating the immune system is in part due to their interaction with the receptors of pathogen-associated molecular patterns (PAMPs). Toll-like receptor (TLR) and the Nod-like (nucleotide oligomerization domain) receptor families, for example, mediate the cellular response to PAMPs [44, 45]. Different classes of TLRs each recognize a specific molecular pattern. Briefly, TLRs 1, 2, 4, 5 and 6 recognize molecular patterns associated with bacteria. On the other hand, TLRs 3 and 7 are specialized in the recognition of molecular patterns associated with viral dsRNA and ssRNA, respectively. While TLRs 8, 9 and 13 recognize patterns of viruses and bacteria concomitantly, associated with ssRNA, DNA CpG patterns and ribosomal RNA sequences, respectively [46, 47]. The possibility of synergy when different innate receptors are stimulated may further enhance the adaptive immune response [48].

Several vaccine strategies may be employed for delivery of tumor antigens, adjuvants and modulators of the immune response (Table 2). Each strategy has its strengths and weaknesses. Even when meticulously planned, the actual response seen in clinical trials is often unpredictable. The vaccine regimen, number of doses, dosage, route of administration and adjuvant employed are variables that directly influence the type and intensity of the immune response generated. Another important point to be weighed is the mechanism of action, including (i) passive therapies based on the transfer of molecules (such as antibody or cytokine therapies) or mature immune effector cells for example transfer of adoptive T cells, or even CAR-T cell–based therapy; or, (ii) active therapies including classical therapeutic vaccines and those based on DCs to establish effector immune responses against tumors.

Type Generic mechanism Clinical trialsa FDA approved
Protein based
Peptides/proteins Provide epitopes for specific antitumor immune responses. 446/278 Gardasil
Cytokine therapy Modulate positively antitumor immunity. 721 Proleukin (IL2r)
Antibody therapy Selectively target dysfunctional or overexpressed proteins in tumors. 4187 Rituximab, bevacizumab, ipilimumab, pembrolizumab
Gene based
DNA/RNA vaccines Provide epitopes for select antitumor immune responses. 142/80
Recombinant virus based
Adenovirus Gene transfer, including TK, CD and cytokines, among other transgenes. 193
Oncolytic virus Selective infection in tumors promoting cell death. 74 Imlygic
Cell based
Tumor cells Provide wide range of epitopes for select antitumor immune responses. 78
Dendritic cells Provide mature, activated and antigen-loaded dendritic cells for the correct antigen presentation, and consequent generation of effector T cells against the tumors. 574 Sipuleucel-T
Transfer of adoptive T cells To provide T lymphocytes with lithic capacity directed at tumor cells. 77
CAR-T T lymphocytes engineered in vitro that recognizes proteins/tumor epitopes, being endowed with lytic capacity independent of costimulatory molecules. 342 Kymriah

Table 2.

Type of gene transfer used in vaccines and immunotherapy against cancer., search performed April, 2018.

Protein-based immunotherapy combines peptides and/or proteins, aiming to activate antitumor immune responses. This strategy has been particularly effective in preventing oncogenic virus infection, as has been seen with Gardasil and Cervarix, which block HPV-associated cervical cancer [49]. The immune responses to structural proteins or viral oncoproteins are likely to be more effective since these antigens are foreign in the body. However, cancer-associated proteins or epitopes, being self-antigens, are naturally less immunogenic and typically associated with immune tolerance; consequently, they are less effective in eliciting immune responses in preclinical cancer models. In this way, delivery systems involving peptides, proteins and DNA/RNA vaccines, although classically used, may be poorly immunogenic and require appropriate pairing with adjuvants [50, 51, 52].

On the other hand, delivery systems based on viral vectors can be used for this purpose and may offer greater immunogenicity. Considering that many viral vectors come from pathogenic viruses such as lentivirus, retroviruses and adenoviruses, there is already a line of defense against these “intruders” that can be raised during immunotherapy. This strategy has inherent advantages, such as the possibility of activating innate immune responses due to a variety of viral molecular patterns that are agonists of TLRs, attracting and helping to mature cells of the adaptive immune response. As for the safety of these vectors, genetic engineering techniques allow the removal of specific genes related to pathogenicity, making them innocuous and safe for human use [53, 54]. In the last few years, several virus-driven therapies have been approved for human use, showing substantial progress in the field of gene therapy. Such approaches include Glybera for lipoprotein lipase deficiency and the oncolytic virotherapy Imlygic [55, 56], CAR-T cell immunotherapies Kymriah and Yescarta [57], as well as Strimvelis for the treatment of ADA-SCID (severe combined immunodeficiency due to adenosine deaminase deficiency) [58] and Luxturna for the treatment of Leber’s congenital amaurosis [59].

The efficiency of immunotherapies may be increased by applying combinations of different strategies. The combination of antibody therapy, cytokine therapy and checkpoint blockade with other immunotherapeutic strategies has been shown to increase antitumor activity [60, 61, 62]. Antibody therapy often targets tumor antigens and/or tumor-promoting proteins. Some antibodies act as blockers of the function of their targets, while others may act as agonists. Additionally, the binding of these antibodies to their targets may direct opsonization or complement-mediated lysis and thereby contribute to the elimination of tumor cells. Another aspect of passive immune therapies is the use of recombinant cytokines, such as IL-2, IL-12 and interferon-α, β and γ [63]. Although both strategies can modulate the immune system to bring improvements, their action is temporary and can only be palliative, requiring successive doses and may provoke serious adverse effects [64, 65]. Checkpoint blockade has been gaining prominence recently and also encompasses the use of monoclonal antibody inhibitors of negative modulators of immune function, such as anti-PD-1, PDL1 and CTLA4 [66, 67, 68].

3.2. Modified dendritic cells as therapeutic vaccines

The presentation of antigens is a crucial event in the genesis of adaptive immune responses. Antigen-presenting cells (APCs) capture proteins in peripheral tissues, process them by proteolytic digestion and, after migrating to secondary lymphoid organs, present them to T lymphocytes in the context of class I or II MHC molecules [69]. In addition to the MHC molecules (HLA in humans), a number of costimulators (such as CD80, CD86, CD40, CD83 and CD14) are also required, important for the complementation of the biochemical signals necessary for the activation of T lymphocytes upon recognition of the presented antigens [70, 71, 72]. The maturation of cytotoxic T lymphocytes is central to the generation of adaptive immunity and, in turn, is one of the major antitumor defenses.

Autologous dendritic cell vaccines can be prepared from the patient’s peripheral blood, with isolation of CD14+ cells and in vitro treatment with GM-CSF and IL-4 for differentiation and maturation of monocyte-derived DCs (Mo-DCs). Next, different techniques can be used to “load” the tumor antigens into the DCs, such as peptides, proteins, DNA or RNA transfection, exosomes or exposure to tumor cell lysates [73, 74]. In addition to the changes that occur in the tumor microenvironment, the tumor is also capable of inducing systemic changes in the host’s immune system, so that the monocytes from cancer patients may result in DCs with altered phenotype and cytokine production, negatively impacting immunotherapy [15]. Thus, immunotherapy with allogeneic DCs represents an interesting alternative. In addition to offering greater availability of DCs (since healthy donors have higher monocyte counts), tissue rejection by antigenic determinants (HLA) may function as an adjuvant.

Barbuto et al. used an interesting strategy for the construction of DC-based therapeutic vaccines for cancer. Healthy donor monocytes are differentiated and matured ex vivo and are subsequently fused to tumor cells by electrical shock, resulting in a hybrid cell. These hybrids are gamma irradiated, to prevent replication, and then administered back to the patient, seeking the generation of immune responses against neoplasms. Although the hybrids were shown to offer limited improvement of mortality rates, longer survival of the treated patients was achieved [75, 76]. Another phase I study in melanoma patients employed immunotherapy using plasmacytoid and myeloid DCs (pDC and mDC, respectively). The results were promising and indicated a survival time of more than 2 years in most of their patients [77, 78].

Currently, more than 500 clinical trials using dendritic cells are being conducted for the treatment of various forms of cancer in different countries. Most of these (324) are in the US, followed by the European Union (120) and China (72) [79]. Although results are very heterogeneous, there is a consensus that the use of these therapies in humans does not present risks or serious side effects.

Sipuleucel-T (Provenge), a dendritic cell-based vaccine for the treatment of metastatic castration-resistant prostate cancer, is the only example approved for use in humans. Its manufacture is done in a personalized manner, which involves the extraction of the patient’s peripheral blood mononuclear cells (PBMCs) by leukapheresis, transport of the cells to Dendreon’s facility (New Jersey, USA) for in vitro culture, maturation of DCs and loading with PA2024 (hybrid protein of GM-CSF and prostate-specific prostatic acid phosphatase, PAP) before returning the cells to the hospital where they will be administered to the patient [80].

Three phase 3 clinical trials supported the approval of sipuleucel-T by the FDA [81, 82, 83]. These studies have demonstrated that sipuleucel-T extended the survival of treated patients by 4.1 months when compared to the control group that received cells processed in a manner similar to sipuleucel-T, however, without activation due to the absence of the recombinant protein. Although this gain in survival seems promising, none of these studies showed significant increase in time to disease progression [84]. However, no side effects were observed in most cases, and T-lymphocyte proliferation was also detected, factors contributing to FDA approval [84]. In practice, the logistics of sending temperature- and time-sensitive material from widely distributed health care institutions to and from a single processing center made this immunotherapeutic strategy cumbersome and relatively expensive, since the total cost of treatment with sipuleucel-T has been reported to be $93,000 to $140,000.00 [80, 85]. Despite the prolonged survival and increased quality of life, this therapeutic option was not sustained and was discontinued.


4. Suicide gene therapy

In cancer gene therapy, different approaches can be used to kill tumor cells. Suicide gene therapy (also called gene-directed enzyme prodrug therapy) is one example where a viral or bacterial gene is introduced in the cancer cell such that it can convert a nontoxic prodrug into its lethal form. The most famous system used in this strategy is herpes simplex virus thymidine kinase gene (HSV-tk) and ganciclovir (GCV) as the prodrug. Expression of the HSV-tk gene leads to production of the enzyme that turns GCV into GCV monophosphate. After this first conversion, cellular kinases metabolize GCV monophosphate into GCV triphosphate, which is an analogue of deoxyguanosine triphosphate. GCV triphosphate causes tumor cell death upon its incorporation into DNA and consequent inhibition of DNA replication [86]. Another example of a suicide gene is the cytosine deaminase gene (CD) of Escherichia coli that catalyzes the hydrolytic deamination of cytosine into uracil, converting the nontoxic antifungal agent 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). This process causes cell death by three main pathways: thymidylate synthase inhibition, formation of (5-FU) RNA and of (5-FU) DNA complexes [86]. More recent systems were developed, including an engineered version of human thymidylate kinase (TMPK) and the prodrug azidothymidine (AZT), which was first tested in leukemia model in vitro and in vivo. Native TMPK catalyzes AZT into AZT monophosphate, the toxic compound, only very slowly, so the engineering of TMPK allows it to act more robustly [87, 88]. In another example, the iCas9 system consists of inducible expression of the caspase-9 gene and administration of the small molecule chemical inducer of dimerization (CID) that leads to caspase-9 dimerization, thus promoting apoptosis [86].

One of the advantages of the suicide gene approach is the bystander effect that consists of a functional effect that may be seen even when only a small percent of cells has been transduced, and thus, tumor regression can occur. The most accepted hypotheses for this phenomenon of killing nontransduced tumor cells are passive diffusion of the drug, passage of the drug through gap junctions and release of soluble factors, forming a local bystander effect [89]. A different approach that relies on the bystander effect involves the use of mesenchymal stem cells (MSCs) to deliver drugs or vectors. The advantage in this case is that HSV-tk–modified MSCs could be effectively delivered to the area of interest and GCV could then be safely administrated systemically. HSV-tk–bearing MSCs home to and infiltrate the tumor region. Consequently, only tumor cells will be affected, while adjacent areas should remain unharmed [90].

Alternatively, the bystander effect may be a consequence of an immune response initiated by suicide gene therapy in vivo, also known as a distant bystander effect. Several articles in the literature have demonstrated a relationship between HSV-tk and immune response. Also called gene-mediated cytotoxic immunotherapy, treatment with HSV-tk promotes innate immune stimulation and infiltration of T cells in tumors [89]. In a clinical trial treating prostate cancer, Ayala and collaborators used an adenoviral vector encoding HSV-tk. In addition to increased apoptosis and decreased microvessel density, they found circulating and activated CD8+ cells and increased IL-12, an important mediator of immune response to tumor cells and viral infection. They also found intratumor CD8+ cells, suggesting the occurrence of both local and systemic responses [91]. Combining suicide and immune gene therapy in an aggressive melanoma model, together HSV-tk and GM-CSF induced a meaningful systemic immune response that was stronger as compared to GM-CSF alone [92]. The induction of an immune response upon CD/5-FC may be less well known [93] but has also been reported [94, 95]. Adenoviral delivery of HSV-tk was tested in a phase III trial, showing increased time to death in patients with high-grade glioma, but it did not increase overall survival [96]; perhaps combining suicide gene therapy with an additional immunotherapy approach could improve response. For example, a current trial is testing the combination of HSV-tk with FMS-like tyrosine kinase 3 ligand (FLT3L) carried by adenoviral vectors in order to promote both tumor cell death and DC activity [97].

Applied as a safety mechanism, HSV-tk is also used to control CAR-T cells. As described in more detail below, the successful clinical experience of engineered CAR-T cells is also associated with serious adverse events where the massive cell killing results in tumor lysis syndrome, an extreme elevation of plasma IL-6 concentrations that can lead to hypotension and respiratory distress in severe cases [98]. Accordingly, suicide gene therapy can be used to kill the CAR-T cells and thus stop the cytokine release syndrome [99]. In a myeloid leukemia model, Casucci and collaborators associated HSV-tk/GCV with CAR-T cells targeting the CD44v6 receptor and compared this approach with the use of the nonimmunogenic suicide gene iCas9 in an attempt to avoid an unwanted immune response, revealing that the second approach was more effective in containing the cytokine release syndrome [100]. At least three clinical trials utilizing iCas9 to control cell fate upon adoptive T cell transfer have been initiated for the treatment of leukemia and lymphoma [79, 101].

In summary, suicide gene therapy is an approach that involves death mechanisms and immunotherapy. The strategy is still evolving from the initial trials and may be an interesting option against cancer and for the improved safety of CAR-T cell therapy.


5. Turning gene therapy into immunotherapy: adenovirus-carrying ARF and interferon-beta

Our own research has focused on the use of nonreplicating viral vectors for the transfer of tumor suppressor genes in combination with an immune-modulating gene (Figure 1). The goal is to induce both cell death and an immune response, thus overcoming the immunosuppressive tumor microenvironment and initiating the cancer immunity cycle. To this end, we have developed an improved vector system that promotes cooperation between gene function and vector performance.

Figure 1.

Schematic representation of our immunotherapy approach. (1) The adenoviral vectors encode either interferon-β (IFNβ) or p19ARF (alternate reading frame, p19ARF in mice and p14ARF in humans) where expression of the cDNA is controlled by a p53 responsive promoter, termed PG. (2) The combination of IFNβ + ARF induces tumor cell death by necroptosis and is associated with the release of immunogenic factors (such as HMGB1, ATP and calreticulin). (3) Immune cells are recruited and activated to attack the tumor.

We have constructed a series of viral vectors where transgene expression is controlled by the tumor suppressor p53, a powerful transcriptional regulator [54, 102, 103]. Moreover, placing the p53 cDNA under the control of the p53-responsive promoter (PGTxβ, or simply PG) establishes an autoregulatory, positive feedback mechanism that was shown to outperform vectors employing a constitutive promoter to express p53. That is, gene expression and cell killing in vitro and in vivo were superior when using our modified vectors to express p53 [104, 105, 106]. We have also looked to p19ARF (alternate reading frame, p19ARF in mice and p14ARF in humans), a functional partner of p53, to serve as the death-promoting factor in our approach and have observed that it is effectively expressed from our p53-responsive vectors in tumor cells that harbor wild type p53, resulting in activation of p53-mediated cell killing in vitro and in vivo [107]. Admittedly, cell killing mediated by the p53/ARF pathway alone has a limited, but recognized, role in promoting an antitumor immune response [108].

In order to activate the immune response against the tumor, we have added interferon-β (IFNβ) to our therapeutic approach since it is a central player in innate and adaptive immunity [109]. Indeed, the combination of p19Arf and IFNβ is better able to induce melanoma cell death both in vitro and in vivo [110, 111]. Strikingly, the mechanism of cell death involves necroptosis with liberation of the classic markers of immunogenic cell death [111]. In a mouse model of melanoma, we have confirmed the induction of an antitumor immune response in vaccine and immunotherapy settings, with critical involvement of NK cells, CD4+ and CD8+ T cells [112]. In a mouse model of lung carcinoma, we have shown that in situ gene therapy can bring about an antitumor immune response with critical involvement of neutrophils [113]. Together these studies show that our gene transfer approach is an effective immunotherapy [114, 115]. The results to date are promising and research will continue to evolve, with critical development using clinically relevant models, such as testing with patient-derived tumor samples as well as alternative animal models, including canines [116].


6. Oncolytic virotherapy

In 1892, viruses were first noted by humans and it took only a few years for researchers to raise the possibility that some viral infections may interfere in the clinical outcomes of some patients with different types of cancers. In 1904, a transitory spontaneous remission of acute leukemia in a patient after infection with influenza was reported, prompting the observation of additional occurrences of this type and paving the way for the concept of virotherapy [117]. One of the first reports of viruses being deliberately applied as a therapeutic approach for cancer dates back to 1949, when Herman A. Hoster and colleagues evaluated the clinical outcome of 21 Hodgkin’s disease patients after intentional exposure to Hepatitis B virus [118]. Some years after that, Newman and Southam evaluated the use of several different viruses (vaccinia, mumps, West Nile, dengue, among others) for the treatment of advanced cancer in 57 patients, though no remarkable clinical outcome was observed [119].

Concomitant with the expansion of knowledge in the field of virology, additional protocols describing novel attempts to establish cancer virotherapy were reported, including the use of an array of different virus species, such as adenovirus, Coxsackie, and Epstein-Barr. Despite the new investigations in the 1970s, the threshold of “transitory response” could not be surpassed due to adverse events, such as neurotoxicity, possibly associated with technological limits related to the handling of viruses, for example, the lack of genetic engineering tools needed for the development and testing of more effective and safer versions [120].

With the advances in molecular and cellular biology as well as animal models for cancer research, the perspective of taking oncolytic virotherapy (OV) from bench to the bedside became feasible. For example, a report in 1991 described the construction of a modified herpes simplex virus (HSV-1), which was thymidine kinase-negative and attenuated for neurotoxicity [121]; thus, a critical step was taken to advance the technology of OV.

By definition, OV encompasses native or genetically engineered viruses whose replication is restricted to tumor cells. As per the immunotherapy trend, OV is increasingly gaining attention due to its performance in clinical trials where it is used to treat several types of cancers. With the 2015 approval of Imlygic (talimogene laherparepvec, OncoVex, T-VEC, an HSV-based oncolytic virus) by the FDA and the EMA (European Medicines Agency) for the treatment of unresectable melanoma, the principle of taking advantage of viral replication in order to treat cancer is now an established therapeutic approach.

6.1. Targeting and mechanism of OV

Even in the absence of tools to genetically modify viruses in order to make them safer, in the 1950s, Alice Moore observed that it was possible to generate virus strains with higher oncolytic capacity and more tumor specificity through adaptation. In particular, the oncolytic features of Russian encephalitis virus were enhanced after 20–30 passages in the Sarcoma 180 cell line as compared to the original strain, leading to the idea that the tumor cells could exert an evolutionary pressure upon the virus, favoring those particles adapted to replicate in the tumor [122].

After the development of techniques for the manipulation of DNA, these tools were used to break down the barriers for the development of virotherapy. Thus, undesirable virulence could be mitigated by eliminating key genes from the viral genome, generating attenuated viruses. The viral genome often codes important proteins that regulate its replication in postmitotic cells. For example, the thymidine kinase (TK) gene is associated with DNA synthesis and cell cycle progression [123]. Taking advantage of this information, Martuza and collaborators showed that HSV lacking the gene coding for TK could replicate in dividing cells, but replication was hampered in quiescent cells, in line with the need for selective replication in tumor cells. In an animal model of glioma, locally administrated mutant HSV led to inhibition of tumor growth and showed decreased neurotoxicity [121]. Alternatively, the viral life cycle may be guided by cellular or virus-encoded microRNAs that alter the level of expression of cell-specific proteins [124].

In addition to the aforementioned approaches, tumor selectivity may be achieved by directing the interactions between the virus particle and the target cell. The retargeting of the viral particles can be achieved in different ways, such as the genetic modification of viral proteins so that they gain specificity for a particular cell surface protein. Alternatively, the use of bispecific adapters mediates the interaction of native capsid proteins with a specific cellular receptor. The virus may also be detargeted, that is, modified so that it no longer interacts with nontumor cells [125].

Besides the transductional targeting, the tropism can be also altered at the transcriptional level by using a tissue-specific promoter to regulate the expression of genes critical for viral replication. As an example, in order to produce adenovirus whose replication is restricted to prostate cancer cells, expression of the E1A adenoviral gene (essential for regulating adenoviral replication) was placed under the control of the prostate-specific antigen (PSA) promoter, leading to an adenovirus that is only able to replicate in prostate cells [126].

Viruses themselves are entities capable of subverting the cell replication machinery and making a favorable environment for their own replication, which occasionally leads to cell death by lysis when the new viral particles are released and the infection cycle continues, increasing the initial quantity of viral particles that is then only limited by the decreased number of target cell as well as by the direct action of the immune system through an antiviral response. In addition to lysis due to viral replication, some viruses can produce proteins that trigger molecular pathways that lead to cell death, as is the case for adenovirus, whose E3-11.6 K transcript is found to be important for the lysis of infected cells [127, 128]. However, more recently, it was found that the immune system, concomitant to the intrinsic effect of oncolytic infection, plays an important role.

After infection, more precisely after cell lysis, the release of intracellular content participates in the activation of both innate and adaptive immune responses against tumor- and virus-associated antigens, potentially reverting the intrinsic immune tolerance of the tumor microenvironment [129]. After rupture of the cellular membrane by the virions, the following release of PAMPs and DAMPs induces the activation of type I interferon, Toll-like receptor–mediated molecular pathways and the production of cytokines, which culminate in the recruitment and activation of antigen-presenting cells (APCs) and the subsequent establishment of a memory immune response [130].

6.2. Oncolytic virotherapy makes its mark: oncolytics with regulatory approval for the treatment of cancer

In 2005, Oncorine (H101, Onyx-015), an adenovirus-based oncolytic developed by Shanghai Sunway Biotech, was approved by State Food and Drug Administration, China (SFDA), for the treatment of head and neck squamous cell carcinoma [131]. Oncorine is a modified adenovirus whose E1B and E3 genes are deleted, leading to a virus that, it was originally thought, should only replicate in cells that lack p53 activity, mainly tumor cells [132, 133], though other mechanisms have been proposed for Oncorine’s tumor selectivity [134]. Its precursor, Onyx-15, showed good performance in clinical trials, especially when combined with additional therapeutic approaches, and was well tolerated and safe [135], with no therapy-associated severe adverse events when administered intratumorally in gliomas [136]. In addition to its safety profile, Onyx-15 administration may be associated with some clinical improvement for patients with metastatic colorectal cancer who failed the first-line therapy [137] and those with hepatobiliary tumors not eligible for surgical resection [138].

In 2015, the FDA and the EMA approved an OV based on a modified herpes simplex virus (HSV-1) for the treatment of melanoma. Imlygic (OncoVex, T-VEC, talimogene laherparepvec) expresses granulocyte-macrophage colony-stimulating factor (GM-CSF), while viral genes ICP34.5 and ICP47 were deleted, modifications that conferred better replication in tumor cells and stimulation of an antitumor immune response [30]. After showing safety and antitumor activity in experimental models [30], Imlygic was then administered in a phase I clinical trial, in patients with cutaneous or subcutaneous metastases from refractory head and neck carcinoma, melanoma, breast and gastrointestinal adenocarcinoma, being well tolerated and provoking only mild adverse events (local erythema and fever) [139]. Encouraged by these results, efficacy was assessed in a phase II clinical trial carried out with 50 stages III and IV melanoma patients. In this study, mild adverse events were observed and there was a 26% Response Evaluation Criteria in Solid Tumors (RECIST) response rate, including 8 complete and 5 partial responses [140]. Based on these positive results, an open-label phase III study was carried out where therapy with Imlygic was compared to treatment with GM-CSF, revealing high tolerance to the treatment, and a higher durable response rate (DRR) and also overall survival compared to the GM-CSF treatment, results that culminated in the first FDA and EMA approval of an OV [141].


7. CAR-T cells

An emerging and exciting subject in cellular therapies relies on the engineering of cytotoxic T cells and natural killer cells so they can recognize specific antigens on the cell membrane and induce cell death without reliance on MHC or costimulator expression. Even though infiltrating T cells may recognize tumor antigens, they may be unable to induce a cytotoxic response due to a strong inhibitory microenvironment [142]. The modification of patients’ T cells to express a chimeric antigen receptor (CAR) creates the opportunity to induce a strong cytotoxic response against the tumor even in the face of negative signals [143].

Transmembrane CAR receptors have two main functions: the first is to recognize a specific antigen present only in the membrane of tumor cells. The second is to induce signal transduction independently of other costimulatory signals, culminating in the release of cytotoxic signals and T cell proliferation [144]. Physiologically, the activation of a cytotoxic T cell is mediated by a T cell receptor (TCR) in an MHC-dependent context. Though this antigen-receptor interaction is insufficient to bring about cell killing, it is imperative that other transmembrane receptors interact, authorizing T cells to exert their cytotoxic function. Moreover, the tumor has several mechanisms to evade T cell responses, from losing the MHC complex to expressing inhibitory molecules that induce T cell exhaustion and anergy. Therefore, modifying the TCR so they do not depend upon other authorizing signals has proven an exciting strategy [142].

Structurally, a CAR has an extracellular component responsible for recognizing the antigen of interest, comprised of a single-chain variable fragment (scFv), followed by a spacer region whose length may vary, a transmembrane region (TM), and an intracellular domain composed of one or more signaling components associated with T cell activation. The first generation included, on the intracellular domain, the ζ-chain, a portion of the T cell receptor responsible for its activity. Improved understanding of the complementary signals needed for activation lead to the development of second-generation CARs, which include a CD28 costimulatory domain, thus ensuring full activation of the T cell. The third generation included other transduction signaling domains, preferentially originating from transmembrane proteins derived from the TNF superfamily, such as CD27, 4-1BB and OX40. All of them can transduce signals resulting in survival, proliferation and maintenance of T cells. The fourth generation uses a vector to deliver, in addition to CAR, cytokine genes, such as IL-2 or IL-12, whose expression changes the tumor microenvironment in favor of T cell activity [144].

The first insight into the development of a chimeric transmembrane receptor that could activate cytotoxic T cells came in 1989 by Gross and colleagues. And in 2017, the FDA approved the first two CAR-T cell therapies in rapid succession. These CARs target CD19, a molecule expressed only in B-lymphocytes, an approach shown to be a powerful second-line treatment against B cell acute lymphoblastic leukemia (B-ALL) (Kymriah—tisagenlecleucel, August 2017 [145]) and certain B cell lymphomas (Yescarta—axicabtagene ciloleucel, September 2017 [146]). While both present a scFv against CD19, Kymriah uses the 4-1BB whereas Yescarta uses CD28 as costimulatory domains. The success in clinical trials ranged from 70 to 94%, making these treatments a breakthrough in gene and immunotherapy [144]. However, there are cytotoxic effects that in some cases can be intense, caused by the killing of large numbers of cancer cells that release cytokines and waste products, leading to harmful consequences in the patients. Thus, much more is needed to understand and manage the side effects of these new and promising therapies, such as the inclusion of a suicide gene to eliminate overactive CAR-T cells [147].

Despite the incredible potential of this therapeutic strategy, CAR-T cells have some limitations that prevent their effective use in the fight against a wide range of tumors. Among them, the most troubling is the lack of a perfect antigen present only in tumor cells but not in other tissues. Tandem CAR and inhibitory chimeric antigen receptors (iCAR) are some of the strategies with the greatest potential to overcome this barrier. Tandem CAR consists of two chimeric receptors designed to provide costimulatory signals in response to the recognition of two different antigens [144]. Only after the recognition of both signals are the tandem CAR cells activated. On the other hand, iCAR aims to inhibit T cell activity as soon as the second specific antigen is recognized [144].This second antigen does not exist in tumor cells, so when the iCAR-T cells find it, they are inhibited and leave nontumor cells unscathed.

In some studies, the inhibitory molecules used in the construction of iCAR-T cells are derived from the intracellular domains of proteins often expressed by tumors and whose function is to evade the immune system. Well-known examples are the receptors CTLA-4 and PD-1 that reduce the potency of TCR signaling. The fusion of their intracellular domain to a CAR also inhibits signaling, resulting in decreased cytokine production, limited lymphocyte motility and reduced target cell lysis [144].

Another hindrance to the application of CAR cell therapies is their large-scale production. The usual steps to produce CAR cells are based on extraction of cells from the patient, genetic engineering of NK or T cells, expansion and infusion in the patient. Due to the laborious process, few health care institutions are prepared to produce CAR cells. And off-site preparation of the CAR cells presents extensive logistical challenges. Thus, the production of the CAR cells is one of the principle factors that promote the high cost of this therapy. In a remarkable research conducted by Smith and colleagues [148], they have developed an approach that may show a way around this problem. In a mouse model, they have modified the circulating T cells within the animal’s own body. The strategy is based on the transfection of the CAR gene using β-amino-ester–based nanoparticles. For this, nanocarriers were coated with CD3, a lymphocyte surface antigen. The recognition of this antigen induces the endocytosis of the nanocarriers by the lymphocytes. Furthermore, peptides containing microtubule-associated sequences (MTAS) and nuclear localization signals (NLS) were added to the polymer, facilitating the rapid import of its genetic load through microtubule transport machinery. Alternative approaches include the use of viral vectors and the use of transposon/transposase systems, such as sleeping beauty, that promote integration of the CAR sequence in the host DNA [148].

Instead of a complicated scenario of transporting of patients’ cells to and from specialized facilities, methodology enabling in situ modification of T cells implies that nanoparticles, virus and other vectors containing the CAR sequence can be produced in a central location, packaged and shipped to any hospital. All that is needed is a syringe to inject the vector into the bloodstream of the patient. As the nanoparticles are stable, this enables long-term storage, reducing the cost of this medical technology and permitting the sale of CAR cell therapies at more affordable prices.


8. Conclusions

Clearly, cancer immunotherapy can be achieved by a variety of interventions that share the common goal of boosting the antitumor immune response. These modalities may target distinct points along the cancer immunity cycle, from inducing immunogenic cell death, promoting antigen presentation and culminating in activation of innate and adaptive responses, including cytolytic T cell activity, which can then further promote antitumor immunity since tumor cell killing would reinitiate and propagate the cycle [149]. Moreover, distinct points in the cancer immunity cycle may be targeted simultaneously, enhancing even more the antitumor response.

As shown here, gene transfer plays a critical role in several key cancer immunotherapies. Vaccines, suicide gene therapy, simultaneous induction of cell death and immune response, OV and CAR-T cells all benefit from gene transfer. While the gene transfer technology will continue to evolve, the therapeutic benefit of genetically modifying cells in order to alter their function will certainly continue to be a central theme in cancer immunotherapy. The approval of Imlygic (FDA and EMA), Yescarta and Kymriah (FDA and EMA), as well as the commercialization of Oncorine (China) show that immunotherapies involving some component of gene transfer are now well established.

In addition, we expect that future approaches will rely on multiple immunotherapies that work in harmony. For example, checkpoint blockade along with the gene transfer interventions should bring about strategic combinations of inducing cell death, tumor-specific immune response and maintenance of cytolytic T cell activity. Challenges remain to be addressed, such as avoiding adverse effects, proper monitoring criteria, identification of adequate biomarkers and definition of a reasonable price tag for cutting edge, personalized interventions. Thus, immunotherapies require further study. As such future developments unfold, gene transfer technologies are expected to remain as crucial components of cancer immunotherapy.



We are grateful for the funding that supported this effort, including the Sao Paulo Research Foundation (FAPESP, grant 15/26580-9 and fellowships 13/16074-3, PRDV; 16/18197-3, ILV; 17/23068-0, OLDC; 17/25284-2, OAR) and the National Council of Scientific and Technical Development (CNPq, fellowship 302888/2017-9, BES).


Conflict of interest

The authors have no conflicts of interest.


  1. 1. Ehrlich P. Uber den jetzigen Stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde. 1909;5:273-290
  2. 2. Burnet F. The Concept of Immunological Surveillance. Oxford, UK: Pergamon Press; 1970
  3. 3. Thomas L. On immunosurveillance in human cancer. The Yale Journal of Biology and Medicine. 1982;55(3-4):329
  4. 4. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674
  5. 5. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-148
  6. 6. Teng MW, Galon J, Fridman W-H, Smyth MJ. From mice to humans: Developments in cancer immunoediting. Journal of Clinical Investigation. 2015;125(9):3338
  7. 7. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nature Reviews Immunology. 2006;6(10):715-727
  8. 8. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. Apr 26, 2001;410(6832):1107-1111
  9. 9. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415
  10. 10. Van Den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Current Opinion in Immunology. 1997;9(5):684-693
  11. 11. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annual Review of Immunology. 2004;22:329-360
  12. 12. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, et al. Recognition of tumors by the innate immune system and natural killer cells. Advances in Immunology. 2014;122:91-128
  13. 13. Curiel TJ. Tregs and rethinking cancer immunotherapy. Journal of Clinical Investigation. 2007;117(5):1167
  14. 14. Platten M, Wick W. Tregs in gliomas—The jury is still out. Neuro-Oncology. 2015;17(6):769-770. DOI: 10.1093/neuonc/nov034
  15. 15. Ramos RN, Moraes CJD, Zelante B, Barbuto JAM. What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Clinical and Developmental Immunology. 2013;2013:e806025
  16. 16. Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget. Feb 2018;9(9):8584-8596
  17. 17. Yu DP, Cheng X, Liu ZD, Xu SF. Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. Oncology Letters. Aug 2017;14(2):1568-1580
  18. 18. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. Dec 2011;480(7378):480-489
  19. 19. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Letters. Feb 2006;232(2):123-138
  20. 20. Trinh VA, Joseph J, Hwu WJ. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma—A clinical update. Discovery Medicine. Jan 2018;25(135):31-40
  21. 21. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine. Sep 2015;373(13):1270-1271
  22. 22. Ali OA, Lewin SA, Dranoff G, Mooney DJ. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunology Research. Feb 2016;4(2):95-100
  23. 23. Duraiswamy J, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. Cancer Research. Jan 2014;74(2):633-634; discussion 5
  24. 24. Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine. Jan 3, 2018;10(422):eaao1641
  25. 25. Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine. Jan 3, 2018;10(422):eaam7577
  26. 26. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clinical Cancer Research. Jan 2010;16(1):338-347
  27. 27. Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, et al. Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. Journal of Translational Medicine. Jul 2015;13:214
  28. 28. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Annals of Surgery. Feb 2011;253(2):328-335
  29. 29. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urologic Oncology. Sep–Oct 2006;24(5):419-424
  30. 30. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy. Feb 2003;10(4):292-303
  31. 31. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nature Immunology. Aug 2016;17(9):1025-1036
  32. 32. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opinion on Biological Therapy. Jul 2011;11(7):855-873
  33. 33. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine. Feb 2018;378(5):449-459
  34. 34. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of Ibrutinib. Journal of Clinical Oncology. Sep 2017;35(26):3010-3020
  35. 35. Quintás-Cardama A. CAR T-cell therapy in large B-cell lymphoma. New England Journal of Medicine. Mar 2018;378(11):1065
  36. 36. Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): Combination or built-in CAR-T. International Journal of Molecular Sciences. Jan 2018;19(2):e340
  37. 37. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. May 15, 2015;348(6236):803-808
  38. 38. Steinman RM, Mellman I. Immunotherapy: Bewitched, bothered, and bewildered no more. Science. Jul 9, 2004;305(5681):197-200
  39. 39. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. The American Journal of the Medical Sciences. 1893;5:487-511
  40. 40. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. The Journal of urology. Jul 1980;124(1):38-40
  41. 41. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Reviews. Drug Discovery. Sep 2003;2(9):727-735
  42. 42. O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomolecular Engineering. 2001;18(3):69-85
  43. 43. Lima KM, dos Santos SA, Rodrigues JM Jr, Silva CL. Vaccine adjuvant: It makes the difference. Vaccine. 2004;22(19):2374-2379
  44. 44. Takeda K, Akira S. TLR signaling pathways. Seminars in Immunology. Feb 2004;16(1):3-9
  45. 45. Inohara C, McDonald C, Nunez G. NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease. Annual Review of Biochemistry. 2005;74:355-383
  46. 46. Delneste Y, Beauvillain C, Jeannin P. Innate immunity: Structure and function of TLRs. Medecine Sciences. Jan 2007;23(1):67-73
  47. 47. Takeda K, Akira S. Toll-like receptors in innate immunity. International Immunology. Jan 2005;17(1):1-14
  48. 48. Trinchieri G, Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nature Reviews. Immunology. Mar 2007;7(3):179-190
  49. 49. Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. Journal of Clinical Medicine. Apr 3, 2015;4(4):614-633
  50. 50. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine. Mar 1998;4(3):321-327
  51. 51. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. The Lancet Oncology. Jan 2014;15(1):59-68
  52. 52. Robinson HL, Pertmer TM. DNA vaccines for viral infections: Basic studies and applications. Advances in Virus Research. 2000;55:1-74
  53. 53. Panicali D, Davis SW, Weinberg RL, Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: Biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proceedings of the National Academy of Sciences. 1983;80(17):5364-5368
  54. 54. Bajgelman MC, Strauss BE. Development of an adenoviral vector with robust expression driven by p53. Virology. Feb 5, 2008;371(1):8-13
  55. 55. Valdmanis PN, Lisowski L, Kay MA. rAAV-mediated tumorigenesis: Still unresolved after an AAV assault. Molecular Therapy. Nov 2012;20(11):2014-2017
  56. 56. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Science. Oct 2016;107(10):1373-1379
  57. 57. Ledford H. Engineered cell therapy for cancer gets thumbs up from FDA advisers. Nature. Jul 12, 2017;547(7663):270
  58. 58. Monaco L, Faccio L. Patient-driven search for rare disease therapies: The Fondazione Telethon success story and the strategy leading to Strimvelis. EMBO Molecular Medicine. Mar 2017;9(3):289-292
  59. 59. FDA. FDA Approves Novel Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss. FDA, Silver, Spring: MD, USA; Available from:
  60. 60. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: A road map. Journal for Immunotherapy of Cancer. 2017;5:16
  61. 61. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews. Drug Discovery. Aug 2015;14(8):561-584
  62. 62. Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, et al. Dendritic cells and programmed death-1 blockade: A joint venture to combat cancer. Frontiers in Immunology. 2018;9:394
  63. 63. Vazquez-Lombardi R, Roome B, Christ D. Molecular engineering of therapeutic cytokines. Antibodies. 2013;2(3):426-451
  64. 64. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer. Jan 2004;4(1):11-22
  65. 65. Baldo BA. Side effects of cytokines approved for therapy. Drug Safety. Nov 2014;37(11):921-943
  66. 66. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. Dec 2017;18(12):e731-ee41
  67. 67. Cameron F, Whiteside G, Perry C. Ipilimumab: First global approval. Drugs. May 28, 2011;71(8):1093-1104
  68. 68. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. Mar 22, 2012;12(4):252-264
  69. 69. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annual Review of Immunology. 2002;20(1):621-667
  70. 70. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Medicine. 1999;5(4):405-411
  71. 71. Kinsey GR, Okusa MD. Expanding role of T cells in acute kidney injury. Current Opinion in Nephrology and Hypertension. 2014;23(1):9
  72. 72. Pinho MP, Bergami-Santos PC, Barbuto JAM. T cell stimulation by dendritic cell-tumor cell hybrids is enhanced in the presence of free dendritic cells. Journal for Immunotherapy of Cancer. 2013;1(1):1
  73. 73. Palucka K, Banchereau J. Dendritic cell-based cancer therapeutic vaccines. Immunity. Jul 25, 2013;39(1):38-48
  74. 74. Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK, Barbuto JAM. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Frontiers in Immunology. 2015;5:692
  75. 75. Barbuto JAM, Ensina LF, Neves AR, Bergami-Santos PC, Leite KR, Marques R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunology, Immunotherapy. 2004;53(12):1111-1118
  76. 76. Pinho MP, Sundarasetty BS, Bergami-Santos PC, Steponavicius-Cruz K, Ferreira AK, Stripecke R, et al. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Cytotherapy. 2016;18(4):570-580
  77. 77. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clinical Cancer Research. May 1, 2016;22(9):2155-2166
  78. 78. Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic cell-based immunotherapy: State of the art and beyond. Clinical Cancer Research. Apr 15, 2016;22(8):1897-1906
  79. 79. NIH. April 2018. Available from:
  80. 80. Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: An evidence-based review of its place in therapy. Core Evidence. 2015;10:1-10
  81. 81. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine. 2010;363(5):411-422
  82. 82. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Journal of Clinical Oncology. 2006;24(19):3089-3094
  83. 83. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-3679
  84. 84. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. Pharmacy and Therapeutics. Apr 2011;36(4):197-202
  85. 85. Miller D. Dendreon's Provenge Costs the Same as Chemotherapy. Minyanville; 2010. Available from: [Accessed: Jun 2018]
  86. 86. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: Where do we stand now? Cancer Letters. Nov 28, 2012;324(2):160-170
  87. 87. Sato T, Neschadim A, Lavie A, Yanagisawa T, Medin JA. The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer. PLoS One. 2013;8(10):e78711
  88. 88. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Molecular Therapy: The Journal of the American Society of Gene Therapy. May 2007;15(5):962-970
  89. 89. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development. Journal of Cellular Biochemistry. Aug 2011;112(8):1969-1977
  90. 90. Nowakowski A, Drela K, Rozycka J, Janowski M, Lukomska B. Engineered mesenchymal stem cells as an anti-cancer trojan horse. Stem Cells and Development. Oct 2016;25(20): 1513-1531
  91. 91. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Molecular Therapy: The Journal of the American Society of Gene Therapy. Apr 2006;13(4):716-728
  92. 92. Villaverde MS, Combe K, Duchene AG, Wei MX, Glikin GC, Finocchiaro LM. Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. International Immunopharmacology. Sep 2014;22(1):167-175
  93. 93. Eisold S, Antolovic D, Schmidt J, Wiessner R, Klar E, von Knebel-Doeberitz M, et al. Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model. European Surgical Research. 2006;38(6):513-521
  94. 94. Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. Jun 1, 2016;8(341):341ra75
  95. 95. Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, Montellano TT, Mendoza D, Mitchell LA, et al. A retroviral replicating vector encoding cytosine deaminase and 5-FC induces immune memory in metastatic colorectal cancer models. Molecular Therapy—Oncolytics. Mar 30, 2018;8:14-26
  96. 96. Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial. The Lancet Oncology. Aug 2013;14(9):823-833
  97. 97. Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, et al. Single vs. combination immunotherapeutic strategies for glioma. Expert Opinion on Biological Therapy. May 2017;17(5):543-554
  98. 98. Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Molecular Medicine. Sep 2017;9(9):1183-1197
  99. 99. Greco R, Oliveira G, Stanghellini MT, Vago L, Bondanza A, Peccatori J, et al. Improving the safety of cell therapy with the TK-suicide gene. Frontiers in Pharmacology. 2015;6:95
  100. 100. Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood Nov 14, 2013;122(20):3461-3472
  101. 101. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. The New England Journal of Medicine. Nov 3, 2011;365(18):1673-1683
  102. 102. Strauss BE, Costanzi-Strauss E. pCLPG: A p53-driven retroviral system. Virology. Apr 10, 2004;321(2):165-172
  103. 103. Bajgelman MC, Medrano RF, Carvalho AC, Strauss BE. AAVPG: A vigilant vector where transgene expression is induced by p53. Virology. Dec 2013;447(1-2):166-171
  104. 104. Tamura RE, da Silva Soares RB, Costanzi-Strauss E, Strauss BE. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy. Cancer Biology & Therapy. Dec 2016;17(12):1221-1230
  105. 105. Strauss BE, Bajgelman MC, Costanzi-Strauss E. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Therapy. Dec 2005;12(12):935-946
  106. 106. Tamura RE, Hunger A, Fernandes DC, Laurindo FR, Costanzi-Strauss E, Strauss BE. Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector. Human Gene Therapy. Aug 2017;28(8):639-653
  107. 107. Merkel CA, da Silva Soares RB, de Carvalho AC, Zanatta DB, Bajgelman MC, Fratini P, et al. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer. Jun 22, 2010;10:316
  108. 108. Cui Y, Guo G. Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment. International Journal of Molecular Sciences. Nov 19, 2016;17(11):e1942
  109. 109. Medrano RFV, Hunger A, Mendonca SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. Sep 19, 2017;8(41):71249-71284
  110. 110. Merkel CA, Medrano RF, Barauna VG, Strauss BE. Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Therapy. May 2013;20(5):317-325
  111. 111. Hunger A, Medrano RF, Zanatta DB, Del Valle PR, Merkel CA, Salles TA, et al. Reestablishment of p53/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discovery. 2017;3:17017
  112. 112. Medrano RF, Catani JP, Ribeiro AH, Tomaz SL, Merkel CA, Costanzi-Strauss E, et al. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: A novel combination for cancer immunotherapy. Cancer Immunology, Immunotherapy. Apr 2016;65(4):371-382
  113. 113. Catani JP, Medrano RF, Hunger A, Del Valle P, Adjemian S, Zanatta DB, et al. Intratumoral immunization by p19Arf and interferon-beta gene transfer in a heterotopic mouse model of lung carcinoma. Translational Oncology. Dec 2016;9(6):565-574
  114. 114. Medrano RFV, Hunger A, Catani JPP, Strauss BE. Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-beta gene transfer to cancer cells: An inducer of immunogenic cell death. Oncoimmunology. 2017;6(7):e1329072
  115. 115. Hunger A, Medrano RF, Strauss BE. Harnessing combined p19Arf and interferon-beta gene transfer as an inducer of immunogenic cell death and mediator of cancer immunotherapy. Cell Death & Disease. May 11, 2017;8(5):e2784
  116. 116. Strauss BE, Silva GRO, Vieira IDL, Cerqueira OLD, Valle PRD, Medrano RFV, et al. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics. 2018;73:e479s
  117. 117. Dock G. The influence of complicating diseases upon leukaemia. The American Journal of the Medical Sciences. 1904;127:561-592
  118. 118. Hoster HA, Zanes RP, Von Haam E. Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report. Cancer Research. Aug 1949;9(8):473-480
  119. 119. Newman W, Southam CM. Virus treatment in advanced cancer: A pathological study of fifty-seven cases. Cancer. Jan 1954;7(1):106-118
  120. 120. Kelly E, Russell SJ. History of oncolytic viruses: Genesis to genetic engineering. Molecular Therapy: The Journal of the American Society of Gene Therapy. Apr 2007;15(4):651-659
  121. 121. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. May 1991;252(5007):854-856
  122. 122. Moore AE. Viruses with oncolytic properties and their adaptation to tumors. Annals of the New York Academy of Sciences. Jul 1952;54(6):945-952
  123. 123. Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: Residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Molecular and Cellular Biology. May 1991;11(5):2538-2546
  124. 124. Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Molecular Therapy: The Journal of the American Society of Gene Therapy. Mar 2009;17(3):409-416
  125. 125. Verheije MH, Rottier PJ. Retargeting of viruses to generate oncolytic agents. Advances in Virology. 2012;2012:798526
  126. 126. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research. Jul 1997;57(13):2559-2563
  127. 127. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. Journal of Virology. Apr 1996;70(4):2296-2306
  128. 128. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with ADP mutants. Virology. Jun 1996;220(1):152-162
  129. 129. Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, et al. Oncolytic viruses-natural and genetically engineered cancer immunotherapies. Frontiers in Oncology. 2017;7:202
  130. 130. de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage antitumor immunity. Expert Opinion on Biological Therapy. Jul 2015;15(7):959-971
  131. 131. Frew SE, Sammut SM, Shore AF, Ramjist JK, Al-Bader S, Rezaie R, et al. Chinese health biotech and the billion-patient market. Nature Biotechnology. Jan 2008;26(1):37-53
  132. 132. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Current Cancer Drug Targets. 2018;18(2):171-176
  133. 133. Wei D, Xu J, Liu XY, Chen ZN, Bian H. Fighting cancer with viruses: Oncolytic virus therapy in China. Human Gene Therapy. Feb 2018;29(2):151-159
  134. 134. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. Jul 2005;8(1):61-74
  135. 135. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy. Mar 2005;12(5):437-445
  136. 136. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy. Nov 2004;10(5):958-966
  137. 137. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Therapy. Aug 2005;12(8):673-681
  138. 138. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clinical Cancer Research. Feb 2003;9(2):693-702
  139. 139. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clinical Cancer Research. Nov 2006;12(22):6737-6747
  140. 140. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of Clinical Oncology. Dec 2009;27(34):5763-5771
  141. 141. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology. Sep 2015;33(25):2780-2788
  142. 142. Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. Jul 2015;4(7):e1016700
  143. 143. Lim WA, June CH. The principles of engineering immune cells to treat Cancer. Cell. Feb 9, 2017;168(4):724-740
  144. 144. D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: The long and winding road to solid tumors. Cell Death & Disease. Feb 2018;9(3):282
  145. 145. Prasad V. Immunotherapy: Tisagenlecleucel—The first approved CAR-T-cell therapy: Implications for payers and policy makers. Nature Reviews. Clinical Oncology. Jan 2018;15(1):11-12
  146. 146. Alissa Poh. FDA approves second CAR T-cell therapy. Cancer Discovery. Jan 2018;8(1):5-6
  147. 147. Badieyan ZS, Hoseini SS. Adverse effects associated with clinical applications of CAR engineered T cells. Archivum Immunologiae et Therapiae Experimentalis (Warsz). Aug 2018;66(4):283-288
  148. 148. Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nature Nanotechnology. Aug 2017;12(8):813-820
  149. 149. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. Jul 25, 2013;39(1):1-10

Written By

Otto L.D. Cerqueira, Gissele Rolemberg Oliveira Silva, Igor de Luna Vieira, Marlous Vinícius Gomes Lana, Nadine Gimenez, Otavio Augusto Rodrigues, Paulo Roberto Del Valle, Samir Andrade Mendonça and Bryan E. Strauss

Submitted: January 17th, 2018 Reviewed: July 18th, 2018 Published: November 5th, 2018